Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting
Background: Fosfestrol is a low-cost estrogen analog that is useful in the management of metastatic prostate cancer in resource-challenged settings. It acts by altering the pituitary axis, adrenal secretion, and 5-alpha reductase activity. Patients and Methods: The outcomes of metastatic castration-...
Saved in:
| Main Authors: | Jayachandran Perumal Kalaiyarasi, Venkatraman Radhakrishnan, Trivadi S Ganesan, Anand Raja, Prasanth Ganesan, Manikandan Dhanushkodi, Tenali Gnana Sagar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer
by: Fangming Wang, et al.
Published: (2025-05-01) -
USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01) -
Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01) -
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
by: Xiaolin Lu, et al.
Published: (2025-05-01) -
TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)